Calcineurin (CN) inhibitors currently used to avoid transplant rejection block the activation of adaptive immune responses but also prevent the development of tolerance toward the graft, by directly inhibiting T cells. CN, through the transcription factors of the NFAT family, plays an important role also in the differentiation dendritic cells (DCs), the main cells responsible for the activation of T lymphocytes. Therefore, we hypothesized that the inhibition of CN only in DCs and not in T cells could be sufficient to prevent T cell responses, while allowing for the development of tolerance. Here, we show that inhibition of CN/NFAT pathway in innate myeloid cells, using a new nanoconjugate capable of selectively targeting phagocytes in vivo, protects against graft rejection and induces a longer graft acceptance compared to common CN inhibitors. We propose a new generation of nanoparticles-based selective immune suppressive agents for a better control of transplant acceptance.
Colombo, M., Marongiu, L., Mingozzi, F., Marzi, R., Cigni, C., Facchini, F., et al. (2022). Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells. ISCIENCE, 25(10) [10.1016/j.isci.2022.105042].
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells
Colombo M.;Marongiu L.;Mingozzi F.;Marzi R.;Cigni C.;Facchini F. A.;Rotem R.;Valache M.;Stucchi G.;Rocca G.;Gornati L.;Rizzuto M. A.;Salvioni L.;Zanoni I.;Gori A.;Prosperi D.;Granucci F.
2022
Abstract
Calcineurin (CN) inhibitors currently used to avoid transplant rejection block the activation of adaptive immune responses but also prevent the development of tolerance toward the graft, by directly inhibiting T cells. CN, through the transcription factors of the NFAT family, plays an important role also in the differentiation dendritic cells (DCs), the main cells responsible for the activation of T lymphocytes. Therefore, we hypothesized that the inhibition of CN only in DCs and not in T cells could be sufficient to prevent T cell responses, while allowing for the development of tolerance. Here, we show that inhibition of CN/NFAT pathway in innate myeloid cells, using a new nanoconjugate capable of selectively targeting phagocytes in vivo, protects against graft rejection and induces a longer graft acceptance compared to common CN inhibitors. We propose a new generation of nanoparticles-based selective immune suppressive agents for a better control of transplant acceptance.File | Dimensione | Formato | |
---|---|---|---|
Colombo-2022-iscience-VoR.pdf
accesso aperto
Descrizione: Article
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Dimensione
3.47 MB
Formato
Adobe PDF
|
3.47 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.